Gene Symbol | Pearson Correlation Coefficient |
---|---|
MAP3K12 | 0.91 |
SKIV2L | 0.909 |
SUGP2 | 0.909 |
DPH1 | 0.908 |
CMTR1 | 0.905 |
TBCD | 0.904 |
FAM160A2 | 0.901 |
C16orf58 | 0.901 |
HMGXB3 | 0.9 |
QRICH1 | 0.9 |
Gene Symbol | Pearson Correlation Coefficient |
---|---|
OR4F5 | -0.55 |
OR4F29 | -0.502 |
MTRNR2L6 | -0.396 |
MTRNR2L9 | -0.39 |
MTRNR2L10 | -0.369 |
PPBP | -0.315 |
TTLL10 | -0.305 |
HEY2 | -0.292 |
MTRNR2L8 | -0.29 |
FCGR3B | -0.287 |
ID | Drug Name | Action | PubMed |
---|---|---|---|
C009505 | 4,4'-diaminodiphenylmethane | "4,4'-diaminodiphenylmethane affects the expression of GTF2H4 mRNA" | 18648102 |
D001280 | Atrazine | Atrazine results in decreased expression of GTF2H4 mRNA | 22378314 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | "7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of GTF2H4 mRNA" | 19150397 |
D015123 | 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | "7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of GTF2H4 mRNA" | 20018196 |
C006780 | bisphenol A | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of GTF2H4 mRNA | 28628672 |
C006780 | bisphenol A | bisphenol A affects the methylation of GTF2H4 promoter | 27334623 |
C006780 | bisphenol A | bisphenol A affects the expression of GTF2H4 mRNA | 21786754 |
C006780 | bisphenol A | bisphenol A results in increased expression of GTF2H4 mRNA | 25181051 |
D019256 | Cadmium Chloride | Cadmium Chloride results in increased expression of GTF2H4 mRNA | 23741332 |
D019256 | Cadmium Chloride | Cadmium Chloride results in decreased methylation of GTF2H4 promoter | 22457795 |
D002220 | Carbamazepine | Carbamazepine affects the expression of GTF2H4 mRNA | 24752500 |
D003300 | Copper | [ATP7A gene mutant form results in increased abundance of Copper] which results in decreased expression of GTF2H4 mRNA | 15467011 |
D019327 | Copper Sulfate | Copper Sulfate results in decreased expression of GTF2H4 mRNA | 19549813 |
D003375 | Coumestrol | Coumestrol results in increased expression of GTF2H4 mRNA | 19167446 |
C408982 | CPG-oligonucleotide | CPG-oligonucleotide results in decreased expression of GTF2H4 mRNA | 21878529 |
D016572 | Cyclosporine | Cyclosporine results in increased expression of GTF2H4 mRNA | 20106945|2556210 |
D003907 | Dexamethasone | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of GTF2H4 mRNA | 28628672 |
D004008 | Diclofenac | Diclofenac affects the expression of GTF2H4 mRNA | 24752500 |
D004147 | Dioxins | Dioxins affects the expression of GTF2H4 mRNA | 20463971 |
D004610 | Ellagic Acid | Ellagic Acid results in increased expression of GTF2H4 mRNA | 12002526 |
C056493 | imiquimod | imiquimod results in decreased expression of GTF2H4 mRNA | 21878529 |
D007213 | Indomethacin | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of GTF2H4 mRNA | 28628672 |
D007213 | Indomethacin | Indomethacin results in increased expression of GTF2H4 mRNA | 28201806 |
D015056 | 1-Methyl-3-isobutylxanthine | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of GTF2H4 mRNA | 28628672 |
C561695 | (+)-JQ1 compound | (+)-JQ1 compound results in decreased expression of GTF2H4 mRNA | 26254443 |
D048628 | Ketolides | Ketolides analog results in decreased expression of GTF2H4 mRNA | 24967691 |
C482199 | lipopolysaccharide, E coli O55-B5 | "lipopolysaccharide, E coli O55-B5 results in decreased expression of GTF2H4 mRNA" | 24972896 |
C004925 | methylmercuric chloride | methylmercuric chloride results in decreased expression of GTF2H4 mRNA | 23458150 |
D018817 | N-Methyl-3,4-methylenedioxyamphetamine | "N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of GTF2H4 mRNA" | 20188158 |
C406082 | monomethylarsonous acid | monomethylarsonous acid results in increased expression of GTF2H4 protein | 24625837 |
C568376 | MT19c compound | MT19c compound results in decreased expression of GTF2H4 mRNA | 21781307 |
C028007 | nickel monoxide | nickel monoxide results in increased expression of GTF2H4 mRNA | 19167457 |
D010416 | Pentachlorophenol | Pentachlorophenol results in increased expression of GTF2H4 mRNA | 23892564 |
C006253 | pirinixic acid | pirinixic acid results in decreased expression of GTF2H4 mRNA | 18445702 |
D011374 | Progesterone | Progesterone results in increased expression of GTF2H4 mRNA | 19690047 |
D011794 | Quercetin | Quercetin results in increased expression of GTF2H4 mRNA | 21632981 |
C059514 | resveratrol | resveratrol results in increased expression of GTF2H4 mRNA | 12002526 |
C009277 | sodium arsenate | sodium arsenate results in increased expression of GTF2H4 mRNA | 23922661 |
C017947 | sodium arsenite | sodium arsenite results in increased expression of GTF2H4 mRNA | 16014739 |
D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin affects the expression of GTF2H4 mRNA | 21570461 |
D013755 | Tetradecanoylphorbol Acetate | Tetradecanoylphorbol Acetate results in increased expression of GTF2H4 mRNA | 19031421 |
GO ID | GO Term | Qualifier | Evidence | PubMed |
---|---|---|---|---|
GO:0003690 | double-stranded DNA binding | - | IBA | 21873635 |
GO:0003700 | DNA-binding transcription factor activity | - | TAS | 9118947 |
GO:0004003 | ATP-dependent DNA helicase activity | - | IEA | - |
GO:0004672 | protein kinase activity | contributes_to | IDA | 9852112 |
GO:0005515 | protein binding | - | IPI | 17466626 19172752 26496610 |
GO:0008094 | DNA-dependent ATPase activity | contributes_to | IDA | 9852112 |
GO:0008353 | RNA polymerase II carboxy-terminal domain kinase activity | CONTRIBUTES_TO | IBA | 21873635 |
GO:0008353 | RNA polymerase II carboxy-terminal domain kinase activity | contributes_to | IDA | 9852112 |
GO ID | GO Term | Qualifier | Evidence | PubMed |
---|---|---|---|---|
GO:0006281 | DNA repair | - | TAS | 9118947 |
GO:0006283 | transcription-coupled nucleotide-excision repair | - | TAS | - |
GO:0006289 | nucleotide-excision repair | - | IBA | 21873635 |
GO:0006293 | nucleotide-excision repair, preincision complex stabilization | - | TAS | - |
GO:0006294 | nucleotide-excision repair, preincision complex assembly | - | TAS | - |
GO:0006296 | nucleotide-excision repair, DNA incision, 5'-to lesion | - | TAS | - |
GO:0006361 | transcription initiation from RNA polymerase I promoter | - | TAS | - |
GO:0006363 | termination of RNA polymerase I transcription | - | TAS | - |
GO:0006366 | transcription by RNA polymerase II | - | IDA | 9852112 27193682 |
GO:0006366 | transcription by RNA polymerase II | - | TAS | - |
GO:0006367 | transcription initiation from RNA polymerase II promoter | - | TAS | - |
GO:0006368 | transcription elongation from RNA polymerase II promoter | - | TAS | - |
GO:0006370 | 7-methylguanosine mRNA capping | - | TAS | - |
GO:0032508 | DNA duplex unwinding | - | IEA | - |
GO:0033683 | nucleotide-excision repair, DNA incision | - | TAS | - |
GO:0070816 | phosphorylation of RNA polymerase II C-terminal domain | - | IBA | 21873635 |
GO:0070911 | global genome nucleotide-excision repair | - | TAS | - |
GO ID | GO Term | Qualifier | Evidence | PubMed |
---|---|---|---|---|
GO:0000438 | core TFIIH complex portion of holo TFIIH complex | - | IDA | 27193682 |
GO:0000439 | core TFIIH complex | - | IBA | 21873635 |
GO:0005634 | nucleus | - | IDA | 27193682 |
GO:0005654 | nucleoplasm | - | TAS | - |
GO:0005669 | transcription factor TFIID complex | - | IDA | 27193682 |
GO:0005675 | holo TFIIH complex | - | IBA | 21873635 |
GO:0005675 | holo TFIIH complex | - | IDA | 9852112 |
GO:0016607 | nuclear speck | - | IDA | - |
Reactome ID | Reactome Term | Evidence |
---|---|---|
R-HSA-112382 | Formation of RNA Pol II elongation complex | TAS |
R-HSA-113418 | Formation of the Early Elongation Complex | TAS |
R-HSA-162587 | HIV Life Cycle | IEA |
R-HSA-162599 | Late Phase of HIV Life Cycle | IEA |
R-HSA-162906 | HIV Infection | IEA |
R-HSA-1643685 | Disease | IEA |
R-HSA-167152 | Formation of HIV elongation complex in the absence of HIV Tat | IEA |
R-HSA-167158 | Formation of the HIV-1 Early Elongation Complex | IEA |
R-HSA-167160 | RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | IEA |
R-HSA-167161 | HIV Transcription Initiation | IEA |
R-HSA-167162 | RNA Polymerase II HIV Promoter Escape | IEA |
R-HSA-167169 | HIV Transcription Elongation | IEA |
R-HSA-167172 | Transcription of the HIV genome | IEA |
R-HSA-167200 | Formation of HIV-1 elongation complex containing HIV-1 Tat | IEA |
R-HSA-167246 | Tat-mediated elongation of the HIV-1 transcript | IEA |
R-HSA-212165 | Epigenetic regulation of gene expression | IEA |
R-HSA-212436 | Generic Transcription Pathway | TAS |
R-HSA-3700989 | Transcriptional Regulation by TP53 | TAS |
R-HSA-427413 | NoRC negatively regulates rRNA expression | IEA |
R-HSA-5250941 | Negative epigenetic regulation of rRNA expression | IEA |
R-HSA-5663205 | Infectious disease | IEA |
R-HSA-5696395 | Formation of Incision Complex in GG-NER | TAS |
R-HSA-5696398 | Nucleotide Excision Repair | TAS |
R-HSA-5696399 | Global Genome Nucleotide Excision Repair (GG-NER) | TAS |
R-HSA-5696400 | Dual Incision in GG-NER | TAS |
R-HSA-674695 | RNA Polymerase II Pre-transcription Events | TAS |
R-HSA-6781823 | Formation of TC-NER Pre-Incision Complex | TAS |
R-HSA-6781827 | Transcription-Coupled Nucleotide Excision Repair (TC-NER) | TAS |
R-HSA-6782135 | Dual incision in TC-NER | TAS |
R-HSA-6782210 | Gap-filling DNA repair synthesis and ligation in TC-NER | TAS |
R-HSA-6796648 | TP53 Regulates Transcription of DNA Repair Genes | TAS |
R-HSA-72086 | mRNA Capping | TAS |
R-HSA-73762 | RNA Polymerase I Transcription Initiation | TAS |
R-HSA-73772 | RNA Polymerase I Promoter Escape | TAS |
R-HSA-73776 | RNA Polymerase II Promoter Escape | TAS |
R-HSA-73777 | RNA Polymerase I Chain Elongation | TAS |
R-HSA-73779 | RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | TAS |
R-HSA-73854 | RNA Polymerase I Promoter Clearance | TAS |
R-HSA-73857 | RNA Polymerase II Transcription | TAS |
R-HSA-73863 | RNA Polymerase I Transcription Termination | TAS |
R-HSA-73864 | RNA Polymerase I Transcription | TAS |
R-HSA-73894 | DNA Repair | TAS |
R-HSA-74160 | Gene expression (Transcription) | TAS |
R-HSA-74160 | Gene expression (Transcription) | IEA |
R-HSA-75953 | RNA Polymerase II Transcription Initiation | TAS |
R-HSA-75955 | RNA Polymerase II Transcription Elongation | TAS |
R-HSA-76042 | RNA Polymerase II Transcription Initiation And Promoter Clearance | TAS |
R-HSA-77075 | RNA Pol II CTD phosphorylation and interaction with CE | TAS |
R-HSA-8953854 | Metabolism of RNA | TAS |
PMID | Title (Year) | Author | Journal |
---|---|---|---|
22524621 | Lack of association between GTF2H4 genetic variants and AERD development and FEV1 decline by aspirin provocation. (2012 Dec) | Kim JY | Int J Immunogenet |
21976407 | Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer. (2012 Oct) | Buch SC | Mol Carcinog |